Lakefront Biotherapeutics NV current report, Q2 FY2022

Business Context and Reporting Period

This Form 6-K filing is submitted by Galapagos NV, a foreign private issuer, for the month of June 2022. The filing, dated June 23, 2022, serves to incorporate by reference a press release issued on June 21, 2022 (Exhibit 99.1). The registrant is headquartered in Mechelen, Belgium, and files annual reports on Form 20-F.

Financial Metrics

The provided filing text does not contain specific financial data. It acts as a cover document to distribute a press release and does not include revenue, profit, cash flow, margins, debt, or liquidity figures.

Material Changes

The filing text does not detail specific material changes or comparative financial performance versus prior periods. The content is limited to the procedural incorporation of the June 21, 2022, press release.

Guidance, Outlook, and Risks

The filing incorporates a press release containing quotes from Paul Stoffels, MD, Dr. Tol Trimborn, and John Mellors, MD. However, the specific content of these quotes, including any guidance, outlook, management commentary, risks, or unusual items, is not present in the provided text. The filing notes that the press release is attached as Exhibit 99.1 but does not reproduce its substance.

Key Facts for Investor Verification

  • Verify the full content of the June 21, 2022 press release (Exhibit 99.1) to understand the material event triggering this filing.
  • Confirm the specific statements made by Paul Stoffels, MD, Dr. Tol Trimborn, and John Mellors, MD, as these are explicitly referenced but not detailed in the filing text.
  • Note that this document is a procedural filing and does not contain standalone financial statements or operational metrics.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.